pre-IPO PHARMA

COMPANY OVERVIEW

Rheos Medicines is a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease. Our approach targets the underlying cellular metabolism of immune cells to redirect the fate and function of specific cell types to treat immune-mediated disease. By simultaneously identifying new drug targets and characterizing biomarkers of disease we are bringing precision to the treatment of immune-mediated diseases. We have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://rheosrx.com


    CAREER WEBSITE

    https://careers@rheosrx.com


    SOCIAL MEDIA


    INVESTORS

    third-rock-ventures


    PRESS RELEASES


    Jul 20, 2022

    Rheos Medicines Receives FDA “Study May Proceed” Letter to Initiate Phase 1 Clinical Study Under its Investigational New Drug Application for RHX-317 for Treatment of Autoimmune and Inflammatory Diseases


    May 12, 2022

    Rheos Medicines CSO Dania Rabah to Deliver Keynote Address at AAPS National Biotechnology Conference


    May 9, 2022

    Rheos Medicines Announces Publication of New Data to Support Targeting MALT1 to Treat Autoimmune and Inflammatory Diseases


    Apr 14, 2022

    Rheos Medicines Announces New Scientific Advisory Board Members


    Apr 14, 2022

    Rheos Medicines Appoints Katerina Leftheris, Ph.D., as SVP of Drug Discovery and Nabil Uddin, Pharm.D., as VP of Strategy and Business Development


    For More Press Releases


    Google Analytics Alternative